Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21673068&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease Sosa MS; Avivar-Valderas A; Bragado P; Wen HC; Aguirre-Ghiso JAClin Cancer Res 2011[Sep]; 17 (18): 5850-7Systemic minimal residual disease after primary tumor treatment can remain asymptomatic for decades. This is thought to be due to the presence of dormant disseminated tumor cells (DTC) or micrometastases in different organs. DTCs lodged in brain, lungs, livers, and/or bone are a major clinical problem because they are the founders of metastasis, which ultimately kill cancer patients. The problem is further aggravated by our lack of understanding of DTC biology. In consequence, there are almost no rational therapies to prevent dormant DTCs from surviving and expanding. Several cancers, including melanoma as well as breast, prostate, and colorectal carcinomas, undergo dormant periods before metastatic recurrences develop. Here we review our experience in studying the cross-talk between ERK1/2 and p38alpha/beta signaling in models of early cancer progression, dissemination, and DTC dormancy. We also provide some potential translational and clinical applications of these findings and describe how some currently used therapies might be useful to control dormant disease. Finally, we draw caution on the use of p38 inhibitors currently in clinical trials for different diseases as these may accelerate metastasis development.|*MAP Kinase Signaling System/drug effects[MESH]|*Resting Phase, Cell Cycle/drug effects/genetics[MESH]|Breast Neoplasms/metabolism/pathology[MESH]|Extracellular Signal-Regulated MAP Kinases/*metabolism[MESH]|Female[MESH]|Humans[MESH]|Male[MESH]|Mitogen-Activated Protein Kinase 1/metabolism[MESH]|Mitogen-Activated Protein Kinase 11/metabolism[MESH]|Mitogen-Activated Protein Kinase 14/metabolism[MESH]|Mitogen-Activated Protein Kinase 3/metabolism[MESH]|Neoplasm, Residual[MESH]|Neoplasms/drug therapy/*enzymology/genetics/pathology[MESH]|Stress, Physiological[MESH]|p38 Mitogen-Activated Protein Kinases/*metabolism[MESH] |
